Journal
CIRCULATION RESEARCH
Volume 128, Issue 11, Pages 1780-1801Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCRESAHA.120.315894
Keywords
cardiotoxicity; cytokine release syndrome; cytokine storm; immune checkpoint inhibitors; immunology
Funding
- NIH [T32 HL007731-28]
- BMS
- Incyte
- Celgene/BMS
- Janssen
- Bluebird Bio
- Sutro Biopharma
- Teneobio
- Poseida
- Nektar
- Array/Pfizer
- Oncosec
- Parker Institute for Cancer Immunotherapy
- Regeneron
- Replimune
- National Institutes of Health [R01HL141466, R01HL155990, R01HL156021]
Ask authors/readers for more resources
Immune-based therapies have transformed cancer treatments, but cardiovascular complications arising from these therapies present new challenges in cardio-oncology. Understanding the mechanisms of immune activation and associated cardiovascular toxicities is crucial for addressing the cardiovascular sequelae of immunotherapy.
Immune-based therapies have revolutionized cancer treatments. Cardiovascular sequelae from these treatments, however, have emerged as critical complications, representing new challenges in cardio-oncology. Immune therapies include a broad range of novel drugs, from antibodies and other biologics, including immune checkpoint inhibitors and bispecific T-cell engagers, to cell-based therapies, such as chimeric-antigen receptor T-cell therapies. The recognition of immunotherapy-associated cardiovascular side effects has also catapulted new research questions revolving around the interactions between the immune and cardiovascular systems, and the signaling cascades affected by T cell activation, cytokine release, and immune system dysregulation. Here, we review the specific mechanisms of immune activation from immunotherapies and the resulting cardiovascular toxicities associated with immune activation and excess cytokine production.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available